MA53329A - Méthodes de traitement de l'épilepsie - Google Patents
Méthodes de traitement de l'épilepsieInfo
- Publication number
- MA53329A MA53329A MA053329A MA53329A MA53329A MA 53329 A MA53329 A MA 53329A MA 053329 A MA053329 A MA 053329A MA 53329 A MA53329 A MA 53329A MA 53329 A MA53329 A MA 53329A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment methods
- epilepsy treatment
- epilepsy
- methods
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53329A true MA53329A (fr) | 2022-03-02 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053329A MA53329A (fr) | 2018-07-27 | 2019-07-26 | Méthodes de traitement de l'épilepsie |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12558326B2 (fr) |
| EP (1) | EP3829558B1 (fr) |
| JP (1) | JP2021530541A (fr) |
| KR (1) | KR20210061332A (fr) |
| CN (1) | CN112930175A (fr) |
| AU (1) | AU2019310600A1 (fr) |
| BR (1) | BR112021001135A2 (fr) |
| CA (1) | CA3106031A1 (fr) |
| CL (1) | CL2021000196A1 (fr) |
| CO (1) | CO2021002087A2 (fr) |
| CR (1) | CR20210095A (fr) |
| EA (1) | EA202190369A1 (fr) |
| ES (1) | ES2988130T3 (fr) |
| IL (1) | IL280128A (fr) |
| MA (1) | MA53329A (fr) |
| MX (1) | MX2021000987A (fr) |
| PE (1) | PE20211065A1 (fr) |
| PH (1) | PH12021550176A1 (fr) |
| SG (1) | SG11202100682YA (fr) |
| WO (1) | WO2020023923A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| JP2019507111A (ja) | 2015-12-22 | 2019-03-14 | ゾゲニクス インターナショナル リミテッド | 代謝抵抗性フェンフルラミン類縁体およびその使用法 |
| EP3800177B1 (fr) | 2015-12-22 | 2025-01-29 | Zogenix International Limited | Compositions de fenfluramine et procédés de préparation de celles-ci |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| CA3104913A1 (fr) * | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Composes de sulfonamide substitues par heteroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| EA202191079A1 (ru) * | 2018-11-19 | 2021-09-20 | Зодженикс Интернэшнл Лимитед | Способы лечения синдрома ретта с применением фенфлурамина |
| CN114127150A (zh) * | 2019-07-18 | 2022-03-01 | 巴斯夫欧洲公司 | 脲基甲酸酯基分散剂 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| WO2023034115A1 (fr) * | 2021-09-01 | 2023-03-09 | Zogenix International Limited | Fenfluramine pour le traitement de maladies et d'affections démyélinisantes |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR104F (fr) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| DK0762877T3 (da) | 1994-06-03 | 2001-07-16 | Thejmde Trust | Meta-substituerede arylalkylaminer og terapeutiske og diagnostiske anvendelser deraf |
| DE69809222T2 (de) | 1997-05-07 | 2003-08-14 | Galen (Chemicals) Ltd., Dublin | Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron-vorläuferverbindungen |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| PT3035926T (pt) * | 2013-08-19 | 2020-09-01 | Univ California | Compostos e métodos para tratar um distúrbio epiléptico |
| SI3261640T1 (sl) * | 2015-02-25 | 2022-10-28 | The Regents Of The University Of California | 5HT agonisti za zdravljenje epilepsijskih motenj |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| JP2017051788A (ja) | 2016-12-21 | 2017-03-16 | 株式会社三洋物産 | 遊技機 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 US US16/523,568 patent/US12558326B2/en active Active
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/fr not_active Ceased
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 CA CA3106031A patent/CA3106031A1/fr active Pending
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/fr active Active
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021550176A1 (en) | 2021-10-11 |
| EP3829558B1 (fr) | 2024-07-03 |
| MX2021000987A (es) | 2021-06-15 |
| AU2019310600A1 (en) | 2021-02-11 |
| CL2021000196A1 (es) | 2021-12-31 |
| US20200030260A1 (en) | 2020-01-30 |
| IL280128A (en) | 2021-03-01 |
| ES2988130T3 (es) | 2024-11-19 |
| EP3829558A1 (fr) | 2021-06-09 |
| BR112021001135A2 (pt) | 2021-04-20 |
| KR20210061332A (ko) | 2021-05-27 |
| CO2021002087A2 (es) | 2021-04-30 |
| CA3106031A1 (fr) | 2020-01-30 |
| SG11202100682YA (en) | 2021-02-25 |
| CR20210095A (es) | 2021-06-01 |
| US12558326B2 (en) | 2026-02-24 |
| EP3829558C0 (fr) | 2024-07-03 |
| JP2021530541A (ja) | 2021-11-11 |
| PE20211065A1 (es) | 2021-06-09 |
| WO2020023923A1 (fr) | 2020-01-30 |
| EA202190369A1 (ru) | 2021-06-10 |
| CN112930175A (zh) | 2021-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3813808A4 (fr) | Méthodes de traitement de la toxicomanie | |
| EP3645121A4 (fr) | Méthodes de traitement de la maladie de huntington | |
| EP3813647A4 (fr) | Stimulation multimodale de traitement des tremblements | |
| MA45192A (fr) | Traitement d'association | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| EP3813806A4 (fr) | Méthodes de traitement d'un dysfonctionnement mitochondrial | |
| EP3291815A4 (fr) | Méthodes de traitement d'une maladie neurodégénérative | |
| EP3625971A4 (fr) | Traitement d'audio spatial | |
| EP3285776A4 (fr) | Méthodes de traitement d'infections bactériennes | |
| EP3946345A4 (fr) | Méthodes de traitement de la douleur neuropathique | |
| MA54860A (fr) | Méthodes de traitement du myélome multiple | |
| EP3775263A4 (fr) | Compositions et méthodes de traitement de l'acné | |
| MA51678A (fr) | Méthodes de traitement de l'amyotrophie musculaire | |
| MA47504A (fr) | Composés et méthodes de traitement de l'angiocholite biliaire primitive | |
| EP3773633A4 (fr) | Méthodes de traitement de glioblastomes | |
| EP3454793A4 (fr) | Bobines de traitement d'anévrisme | |
| EP3634422A4 (fr) | Méthodes de traitement de la leucodystrophie | |
| EP3393468A4 (fr) | Méthodes pour le traitement d'une maladie immunodéficiente | |
| MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
| EP3383857A4 (fr) | Composés et méthodes de traitement d'infections bactériennes | |
| EP3787625A4 (fr) | Méthodes de traitement du cancer | |
| EP3599983A4 (fr) | Endoscopes et méthodes de traitement | |
| EP3840752A4 (fr) | Méthodes de traitement de la myélofibrose indépendantes du nombre de plaquettes | |
| EP3852816A4 (fr) | Méthodes de traitement de cancer | |
| MA47595A (fr) | Méthodes de traitement d'affections neurodégénératives |